Promus Capital’s Sarepta Therapeutics SRPT Stock Holding History

Promus Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-276	Closed	-$4.72K	–	340
2025 Q2	$4.72K	Buy	+276	New	+$11.8K	﹤0.01%	274

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Promus Capital's SRPT Position: Q3 2025 in Review

Promus Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 276 shares — an estimated $4.72K sold.

Promus Capital first reported a position in SRPT in Q2 2025 and held it in 1 quarter. The position peaked at $4.72K in Q2 2025. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Promus Capital reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Promus Capital sold 276 Sarepta Therapeutics shares in Q3 2025, an estimated $4.72K.
Promus Capital first reported a position in Sarepta Therapeutics in Q2 2025 and held it in 1 quarter.
Promus Capital's Sarepta Therapeutics position peaked at $4.72K in Q2 2025.
320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Promus Capital's 13F filing for Q3 2025, filed 13 Nov 2025.